Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation.

"Potential Conflicts of Interest MP: speaker honoraria from Sanofi‐Aventis, Boehringer‐Ingelheim, Bayer, BMS, Daiichi‐Sankyo, Pfizer (all manufacturers of anticoagulants). MK: speaker honoraria from Bayer, Nippon Boehringer‐Ingelheim, Daiichi‐Sankyo. MC: consulting fees from Boehringer‐Ingelheim, Pfizer/BMS; advisory board Daiichi‐Sankyo. GMDM: consultant/speaker honoraria from Bayer, travel honoraria from Pfizer. ST: travel grants from BMS/Pfizer. GYHL: Consultant and speaker for BMS/Pfizer, Boehringer‐Ingelheim and Daiichi‐Sankyo; no fees are received personally. LHB: consultancy or advisory board fees or speaker's honoraria from Bayer and BMS. PAL: research grants from Bayer, travel grants from Bayer, Pfizer, advisory board compensation from Bayer, Pfizer, Daiichi‐Sankyo, BMS. KT: lecture honoraria (modest) from Daiichi‐Sankyo, Bayer Yakuhin, Nippon Boehringer‐Ingelheim, BMS. DJW: personal fees from Bayer, Portola (manufacturer of the anticoagulant reversal agent andexanet alfa). STE: research support from Pfizer, Daiichi‐Sankyo; compensation from Stago (manufacturer of coagulation testing systems) for educational material; travel/speaker honoraria from Bayer, Boehringer‐Ingelheim, BMS, Daiichi‐Sankyo; advisory board Bayer, Boehringer‐Ingelheim, BMS. The remaining authors declare no relevant conflicts."

"We thank all investigators from the participating cohort studies (listed in Table S5) for their contribution to data collection. This study was supported by the Science Fund Rehabilitation of the University Department of Geriatric Medicine Felix Platter Basel, the Stroke Fund and Scientific Fund of the University Hospital Basel. NOACISP‐LONGTERM was supported by grants from the Swiss Heart Foundation, Daiichi‐Sankyo AG (Switzerland) and Bayer AG (Switzerland). CROMIS‐2 was jointly funded by the Stroke Association and the British Heart Foundation and supported by researchers at the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. UCL acted as the Sponsor for CROMIS‐2, with responsibility for the conduct and management of the study. SAMURAI‐NVAF was supported by a Grant‐in‐Aid (H23‐Junkanki‐Ippan‐010) from the Ministry of Health, Labour and Welfare, Japan and an Intramural Research Fund (H23‐4‐3 and H28‐4‐1) for Cardiovascular Diseases of the National Cerebral and Cardiovascular Center. RAF/RAF‐DOAC has been supported by the Italian Ministry of Health Ricerca Corrente – IRCCS MultiMedica. Open access funding provided by Universitat Basel."